Torrent Pharmaceuticals Limited (NSE: TORNTPHARM)
India
· Delayed Price · Currency is INR | Market Cap | 1.05T |
| Revenue (ttm) | 112.24B |
| Net Income (ttm) | 18.02B |
| Shares Out | n/a |
| EPS (ttm) | 53.25 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | Jun 21, 2024 |
| Volume | 170,973 |
| Open | 3,095.05 |
| Previous Close | 3,094.85 |
| Day's Range | 3,076.00 - 3,128.00 |
| 52-Week Range | 2,025.70 - 3,590.70 |
| Beta | 0.25 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 25, 2024 |
About Torrent Pharmaceuticals
Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India, the United States, Brazil, Germany, and internationally. The company offers products in various therapeutic areas, including cardiovascular, central nervous system, gastro-intestinal, and women healthcare; and dermatology, diabetology, pain management, gynecology, oncology, and anti-infective, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services. The company... [Read more]
Financial Performance
In 2023, Torrent Pharmaceuticals's revenue was 107.28 billion, an increase of 11.51% compared to the previous year's 96.20 billion. Earnings were 16.56 billion, an increase of 33.02%.
Financial StatementsNews
Torrent Pharma Block Deal: 1.04 crore shares or 3% equity worth Rs 3,230 crore change hands
Torrent Pharmaceuticals shares dropped 3.15% to ₹3,114.35 as of 9:19 am on the NSE after a significant large trade. Approximately 1.04 crore shares, equating to 3.1% of equity, exchanged hands at ₹3,1...
Stock to watch today: Torrent Pharma promoter to sell up to 2.9% stake via block deal: Report
Torrent Pharmaceuticals Ltd. is likely to be in focus today as promoter entity Torrent Investments has announced plans to sell up to a 2.9% stake in the company through a block deal. This information ...
Torrent Pharmaceuticals shares in focus as Q2 profit rises 17.4% to ₹453 crore
Torrent Pharmaceuticals has attracted attention after reporting a 17.4% increase in net profit for the second quarter, rising to ₹453 crore. The company’s revenue grew by 8.6%, reaching ₹2,889 crore, ...
Torrent counters faulty drug claim
Torrent Pharmaceuticals Limited strongly denies allegations regarding its Shelcal 500 product, claiming the seized sample is counterfeit and not produced by them. The company has implemented anti-coun...
Torrent Pharma announces US FDA’s inspection conclusion at Madhya Pradesh facility, shares surge over 2%
Torrent Pharmaceuticals announced that the United States Food & Drug Administration (USFDA) conducted a routine GMP inspection at its formulation manufacturing facility in Pithampur, Madhya Pradesh, b...
Torrent Pharma shares surge around 2% after USFDA inspection closure
Torrent Pharmaceuticals (TORNTPHARM) saw its shares increase by 1.96%, trading at ₹3,502.00 at 10:21 AM on the NSE. The stock’s upward movement follows the company’s announcement that its Indrad manuf...
Torrent Pharma’s Indrad facility receives USFDA EIR with VAI Classification
Torrent Pharmaceuticals has announced that its manufacturing facility in Indrad, Gujarat, has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA), with a...